AXGN vs. EDAP, ZYXI, SMLR, ELMD, OM, FONR, VANI, CUTR, BLFS, and EPIX
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Edap Tms (EDAP), Zynex (ZYXI), Semler Scientific (SMLR), Electromed (ELMD), Outset Medical (OM), FONAR (FONR), Vivani Medical (VANI), Cutera (CUTR), BioLife Solutions (BLFS), and ESSA Pharma (EPIX).
AxoGen (NASDAQ:AXGN) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
AxoGen currently has a consensus price target of $10.67, indicating a potential upside of 88.12%. Edap Tms has a consensus price target of $14.67, indicating a potential upside of 107.16%. Given Edap Tms' higher probable upside, analysts plainly believe Edap Tms is more favorable than AxoGen.
AxoGen has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
AxoGen has a net margin of -12.99% compared to Edap Tms' net margin of -35.03%. AxoGen's return on equity of -22.18% beat Edap Tms' return on equity.
AxoGen received 101 more outperform votes than Edap Tms when rated by MarketBeat users. Likewise, 72.59% of users gave AxoGen an outperform vote while only 62.77% of users gave Edap Tms an outperform vote.
AxoGen has higher revenue and earnings than Edap Tms. AxoGen is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.
In the previous week, AxoGen had 7 more articles in the media than Edap Tms. MarketBeat recorded 10 mentions for AxoGen and 3 mentions for Edap Tms. Edap Tms' average media sentiment score of -0.13 beat AxoGen's score of -0.23 indicating that Edap Tms is being referred to more favorably in the news media.
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 62.7% of Edap Tms shares are owned by institutional investors. 7.0% of AxoGen shares are owned by company insiders. Comparatively, 0.2% of Edap Tms shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
AxoGen beats Edap Tms on 13 of the 17 factors compared between the two stocks.
Get AxoGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
